Inside IPEC–Americas: Evaluating Excipient Stability - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside IPEC–Americas: Evaluating Excipient Stability
IPEC's new stability testing guide takes into account the full supply chain's storage conditions.

Pharmaceutical Technology
Volume 33, Issue 9, pp. 74-75

Stability protocols

A stability study, whether following option 1 or 2 as noted above, should be described in the manufacturer's protocol with multiple detailed sections, as outlined below.

Objective. The purpose of conducting a stability study (e.g., to support a new excipient, ongoing evaluation, or to evaluate the impact of a significant change) should be clearly stated.

Scope. The protocol should indicate what excipient(s) are covered by the stability study, especially in cases where the protocol is applied to a "model-product" study.

Selection of the container–closure system. Stability samples should be stored in a container–closure system that provides equal (not better) protection from temperature or humidity than the planned commercial packaging. Stability studies for bulk shipments (e.g., barges, railcars) pose particular problems in design because there is some uncertainty as to how long the excipient may reside in the bulk container. However, extrapolation from data collected using the methods outlined herein is possible when consideration is given to the risk factors to excipient stability posed by the transport containers.

Storage conditions. The stability package should be stored using the specified storage conditions as defined in the protocol or the ambient conditions found in the manufacturer's warehouse. The experiment should be conducted over the longest period of time that the excipient maker warrants the product will continue to conform to the specification.

Sampling plan. The protocol should specify the frequency—schedule from the date of manufacture, which is taken as time zero—of how often samples are to be taken from the stability package for testing. This type of study is best conducted as a kinetics experiment in which samples are tested at less frequent intervals as the excipient approaches its re-evaluation interval.

Stability indicating parameters. If the excipient is known to change during the stated re-evaluation interval, then it should be tested using an appropriate stability indicating test or test that would demonstrate the changes to the product. When there is no direct measurement of the purity of the excipient, stability can be quantified by measuring the change in physical or chemical characteristics. One should also consider comparing the excipient's composition profile at the limit of its re-evaluation interval to that of the excipient at time zero.

Acceptance criteria. The protocol should establish the test results that are expected to support the stated re-evaluation interval. Trend analysis of the data should be used as an indication that the excipient will continue to meet specification through its re-evaluation interval.

Approval and report. The protocol should specify the approval process, including an internal review of the data and conclusions. The final stability report should contain an evaluation of the stability data and the conclusion reached.


The study of excipient stability is best conducted under the environmental conditions that will be encountered during warehousing, shipment, and storage in the market package and a re-evaluation interval should be determined. The new IPEC excipient stability guide aims to establish expectations using a scientific approach for the stability data in support of excipient retest intervals that is appropriate to the various packages typically used to store and transport these pharmaceutical ingredients.

Philip H. Merrell, Ph.D., is the technical market manager at Jost Chemical Co., tel. 314.813.1912,
, and Irwin Silverstein, Ph.D., is chief operating officer at International Pharmaceutical Excipient Auditing, tel. 732.463.8710,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here